Regulus Therapeutics Inc (RGLS) - Medical Equipment - Deals and Alliances Profile
- GDME180566D
- Pages: 32
- October 2018
- Total Views:1297
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its lead product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome; and RGLS4326, an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company's products are used in the therapeutic areas of hepatitis C infection, cardiovascular disease, cancer, fibrosis, immune inflammatory diseases and metabolic diseases, among others. Regulus Therapeutics. Regulus Therapeutics is headquartered in San Diego, California, the US.
Regulus Therapeutics Inc (RGLS)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Regulus Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 10
Regulus Therapeutics Amends Agreement With Biogen Idec 11
Regulus Therapeutics Terminates an Agreement With Biogen Idec For Biomarkers 12
Equity Offering 13
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 13
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 14
Regulus Therapeutics Inc-Key Competitors 16
Regulus Therapeutics Inc-Key Employees 17
Regulus Therapeutics Inc-Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Regulus Therapeutics reports second quarter 2018 financial results 19
May 10, 2018: Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress 21
Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 22
Nov 07, 2017: Regulus Reports Third Quarter 2017 Financial Results and Recent Events 23
Aug 01, 2017: Regulus Reports Second Quarter 2017 Financial Results and Recent Events 24
May 04, 2017: Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring 25
Mar 02, 2017: Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update 26
Corporate Communications 28
Apr 17, 2018: Kathryn J. Collier Joins Regulus Board Of Directors 28
Jun 13, 2017: Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer 29
Jun 01, 2017: Pascale Witz Joins Regulus Board of Directors 30
Other Significant Developments 31
Jul 05, 2018: Regulus Announces Strategic Update and Corporate Restructuring 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List Of Figure
List of Figures
Regulus Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8
List Of Table
List of Tables
Regulus Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 10
Regulus Therapeutics Amends Agreement With Biogen Idec 11
Regulus Therapeutics Terminates an Agreement With Biogen Idec For Biomarkers 12
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 13
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 14
Regulus Therapeutics Inc, Key Competitors 16
Regulus Therapeutics Inc, Key Employees 17
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Regulus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target microRNAs. Its lead product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome; and RGLS4326, an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company's products are used in the therapeutic areas of hepatitis C infection, cardiovascular disease, cancer, fibrosis, immune inflammatory diseases and metabolic diseases, among others. Regulus Therapeutics. Regulus Therapeutics is headquartered in San Diego, California, the US.
Regulus Therapeutics Inc (RGLS)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Regulus Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 10
Regulus Therapeutics Amends Agreement With Biogen Idec 11
Regulus Therapeutics Terminates an Agreement With Biogen Idec For Biomarkers 12
Equity Offering 13
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 13
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 14
Regulus Therapeutics Inc-Key Competitors 16
Regulus Therapeutics Inc-Key Employees 17
Regulus Therapeutics Inc-Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Financial Announcements 19
Aug 09, 2018: Regulus Therapeutics reports second quarter 2018 financial results 19
May 10, 2018: Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress 21
Mar 07, 2018: Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update 22
Nov 07, 2017: Regulus Reports Third Quarter 2017 Financial Results and Recent Events 23
Aug 01, 2017: Regulus Reports Second Quarter 2017 Financial Results and Recent Events 24
May 04, 2017: Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring 25
Mar 02, 2017: Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update 26
Corporate Communications 28
Apr 17, 2018: Kathryn J. Collier Joins Regulus Board Of Directors 28
Jun 13, 2017: Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer 29
Jun 01, 2017: Pascale Witz Joins Regulus Board of Directors 30
Other Significant Developments 31
Jul 05, 2018: Regulus Announces Strategic Update and Corporate Restructuring 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List Of Figure
List of Figures
Regulus Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8
List Of Table
List of Tables
Regulus Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Regulus Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Regulus Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Regulus Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Regulus Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Regulus Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Regulus Therapeutics Enters into Agreement with Biogen Idec for microRNA Biomarkers 10
Regulus Therapeutics Amends Agreement With Biogen Idec 11
Regulus Therapeutics Terminates an Agreement With Biogen Idec For Biomarkers 12
Regulus Therapeutics Plans to Raise USD150 Million in Public Offering of Shares 13
Regulus Therapeutics Raises USD46 Million in Public Offering of Shares 14
Regulus Therapeutics Inc, Key Competitors 16
Regulus Therapeutics Inc, Key Employees 17
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Regulus Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.